Literature DB >> 33765585

ClC-3 promotes paclitaxel resistance via modulating tubulins polymerization in ovarian cancer cells.

Jiezhu Feng1, Zihan Peng1, Lvfen Gao2, Xiurou Yang1, Zele Sun1, Xiuying Hou3, Enze Li1, Linyan Zhu4, Haifeng Yang5.   

Abstract

Epithelial ovarian cancers (EOC) present as malignant tumors with high mortality in the female reproductive system diseases. Acquired resistance to paclitaxel (PTX), one of the first-line treatment of EOC, remains a therapeutic challenge. ClC-3, a member of the voltage-gated Cl- channels, plays an essential role in a variety of cellular activities, including chemotherapeutic resistance. Here, we demonstrated that the protein expression and channel function of ClC-3 was upregulated in PTX resistance A2780/PTX cells compared with its parental A2780 cells. The silence of ClC-3 expression by siRNA in A2780/PTX cells partly recovered the PTX sensitivity through restored the G2/M arrest and resumed the chloride channel blocked. ClC-3 siRNA both inhibited the expression of ClC-3 and β-tubulin, whereas the β-tubulin siRNA reduced the expression of itself only, without affecting the expression of ClC-3. Moreover, treatment of ClC-3 siRNA in A2780/PTX cells increased the polymerization ratio of β-tubulin, and the possibility of proteins interaction between ClC-3 and β-tubulin was existing. Take together, the over-expression of ClC-3 protein in PTX-resistance ovarian cancer cells promotes the combination of ClC-3 and β-tubulin, which in turn increase the ration of free form and decrease the quota of the polymeric form of β-tubulin, and finally reduce the sensitivity to PTX. Our findings elucidated a novel function of ClC-3 in regulating PTX resistance and ClC-3 could serve as a potential target to overcome the PTX resistance ovarian cancer.
Copyright © 2021 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  ClC-3 chloride channel; Ovarian cancer; Paclitaxel; Tubulin

Year:  2021        PMID: 33765585     DOI: 10.1016/j.biopha.2021.111407

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  2 in total

1.  Generation of Two Paclitaxel-Resistant High-Grade Serous Carcinoma Cell Lines With Increased Expression of P-Glycoprotein.

Authors:  Mariana Nunes; Patrícia M A Silva; Ricardo Coelho; Carla Pinto; Albina Resende; Hassan Bousbaa; Gabriela M Almeida; Sara Ricardo
Journal:  Front Oncol       Date:  2021-10-21       Impact factor: 6.244

2.  SOX2 regulates paclitaxel resistance of A549 non‑small cell lung cancer cells via promoting transcription of ClC‑3.

Authors:  Youwei Huang; Xiangyu Wang; Rendong Hu; Guopeng Pan; Xi Lin
Journal:  Oncol Rep       Date:  2022-09-07       Impact factor: 4.136

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.